"Does assessment method influence the prevalence of constipation in patients receiving long-term clozapine?".

BackgroundNone of the studies has evaluated the prevalence of constipation among patients receiving clozapine using different assessment measures.Methods200 patients receiving clozapine for ≥1 year were assessed cross-sectionally for constipation using different assessment methods.ResultsAccording to Rome-III/IV criteria, 62% of participants met criteria for constipation. According to the Bristol Stool Chart, 28% of participants had constipation. The mean total score on the Constipation Assessment Scale was 3.06 (SD: 3.22). In 37.7% of the study sample, the cut-off for the Bowel Function index was met for constipation, with a mean score of 25.01 (SD: 22.64). Higher residual psychopathology was associated with higher severity of constipation as assessed by the Constipation Assessment Scale and Bowel Function Index. A higher severity of constipation, as evaluated by the Constipation Assessment Scale, was associated with higher disability. A higher level of constipation, as assessed using the Constipation Assessment Scale and the Bowel Function Index, was associated with poorer quality of life (QoL).ConclusionThe present study suggests that the prevalence of constipation among patients receiving clozapine varies from 28% to 62%, based on the assessment measure. Additionally, the present study suggests that the presence of constipation has a negative impact on QoL and disability.